MNKD · MannKind
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a daily close below $3.20
Note written ·
Price against the kill line
29.1% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close below $3.20, on record since 10 November 2026. The shares are up 5.9% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close below $3.20, which would erase the gain made since the third-quarter report. Fourth-quarter 2026 Furoscix revenue at or below the first-half 2026 total would also break the case.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 102
- Revenue, change on a year (%)
- +24.0
- Gross margin (%)
- 89.0
- Operating margin (%)
- −2.1
- Free cash flow, four quarters ($M)
- −78.4
- Net cash, cash less debt ($M)
- −223
- Enterprise value to sales (×)
- 3.8
- Free-cash-flow yield (%)
- −5.9
All filed numbers
What MannKind reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 102 | +24.0 | 89.0 | −2.1 |
| first filed | 109 | +42.9 | 86.8 | −0.3 |
| first filed | 90.2 | +15.1 | 91.7 | −1.8 |
| first filed | 112 | +45.8 | 87.6 | −6.9 |
| first filed | 82.1 | +17.2 | 94.5 | 23.0 |
| first filed | 76.5 | +5.7 | 94.0 | 6.9 |
| Pre-tax income ($M) | −23.2 |
| Net income ($M) four quarters: −74.8 | −23.2 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +2.7 |
| Operating cash flow ($M) | −66.2 |
| Capital spending ($M) | 12.2 |
| Free cash flow ($M) | −78.4 |
| Cash and short-term investments ($M) | 96.6 |
| Debt ($M) long-term debt | 319 |
| Net cash, cash less debt ($M) | −223 |
| Deferred revenue ($M) −24.2% on a year | 44.2 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 41.0 |
| Inventory ($M) | 48.5 |
| Shareholders' equity ($M) | −37.3 |
| Market value ($M) | 1,328 |
| Enterprise value, market value plus net debt ($M) | 1,551 |
| Enterprise value to sales (×) | 3.8 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | Not meaningful |
| Free-cash-flow yield (%) | −5.9 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 7.9% of shares outstanding sold short, 5.1 days of average trading to cover, −2.6% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $256K |
| 12 monthsfrom | $259K | $3.2M |
The thesis
MannKind Corporation's shift from inhaled insulin toward Furoscix and royalty income makes the shares modestly more likely than not to beat the S&P 500 over three months. Third-quarter Furoscix net revenue was $22.4 million, and management said fourth-quarter Furoscix revenue should exceed the first half of 2026; the fourth-quarter report, expected around March 2027, settles it.
The shares closed at $4.16 on 12 November 2026, 8.1% above the $3.85 close of 14 August 2026 and 36.1% below the 52-week intraday high of $6.51 set on 8 January 2026. The market has paid for the third-quarter guidance but not for a return to January levels. Cantor Fitzgerald raised its target to $10 (Overweight) and RBC Capital raised its target to $5 (Sector Perform) on 6 November 2026, the session after the 5 November 2026 report.
Bullish and bearish views on MannKind Corporation
The bull case on MannKind Corporation (MNKD), in brief: Furoscix grew again. The bear case: revenue missed estimates.
Bull case
- Furoscix grew again. Net revenue was $22.4 million in the third quarter against $22.2 million in the second (MannKind results, 5 November 2026). ReadyFlow shipments began in mid-September and were about 75% of Furoscix shipments by late October.
- Management set a checkable fourth-quarter goal. CEO Michael Castagna said Furoscix should generate more revenue in the fourth quarter than in the first half of 2026 (5 November 2026 release).
- Royalties grew. Total royalty revenue was $37.5 million, up 12% from $33.3 million a year earlier, which MannKind attributes to higher United Therapeutics Tyvaso DPI (dry-powder inhaler) net revenue (5 November 2026).
- Total revenue and adjusted earnings improved. Revenue was $101.9 million, up 24% from $82.1 million. Adjusted earnings per share of $(0.01) beat the $(0.06) estimate (Benzinga, 5 November 2026).
- Analysts raised targets after the report. Cantor Fitzgerald's target is $10 and RBC Capital's target is $5, both dated 6 November 2026.
Bear case
- Revenue missed estimates. Benzinga reported third-quarter revenue of $101.87 million against a $107.75 million estimate on 5 November 2026.
- Losses widened. The GAAP net loss was $23.2 million, or $0.07 per share, against net income of $8.0 million a year earlier (company results, 5 November 2026).
- Cash fell while debt stayed high. Cash, cash equivalents and investments were $96.6 million at 30 September 2026, down from $111 million at 30 June 2026. The term loan was $319.4 million, and the company reports a $130.0 million royalty-sale liability.
- Afrezza is small and slow. Afrezza net sales were $19.3 million, up 5% from a year earlier (5 November 2026).
- Possible share supply. The 21 August 2026 Form 424B7 prospectus registers up to 12,853,470 shares for resale, including 2,412,632 shares underlying pre-funded warrants. Director Steven Binder sold 39,051 shares at $3.29 on 25 September 2026 under a Rule 10b5-1 plan (SEC Form 4).
Price setup
The shares closed at $4.16 on 12 November 2026, after closes of $4.19 on 11 November 2026, $4.23 on 10 November 2026 and $4.19 on 9 November 2026. The close was $3.76 on 5 November 2026 and $3.90 on 6 November 2026, so the post-report gain has held for four sessions.
The last close sits above the 50-day average of $3.57 and the 200-day average of $3.66, both from adjusted closes as of 12 November 2026. The 52-week closing low is $2.28 on 25 March 2026, and the 52-week intraday high of $6.51 is 56.5% above that close.
The three-month change is 8.1%. Analyst targets span a wide range, from RBC's $5 to Cantor's $10 (both 6 November 2026).
Catalysts ahead
- 17 November 2026: MannKind CEO and CFO give a fireside chat at the UBS conference in London. Management may update its view of ReadyFlow uptake and the fourth-quarter Furoscix goal.
- 18 November 2026: MannKind presents at the Jefferies conference in London. A second management appearance on Furoscix demand, royalties and the term loan.
- ~March 2027 (est.): Fourth-quarter 2026 earnings report; date not announced by MannKind. It tests management's statement that fourth-quarter Furoscix revenue will exceed first-half 2026 revenue.
- 2027 (timing not given): $15 million ralinepag milestone payments anticipated by MannKind. MannKind's 5 November 2026 release anticipates the payments in 2027, which would add non-product cash while the company reports losses.
What would change the view
A daily close below $3.20, which would erase the gain made since the third-quarter report. Fourth-quarter 2026 Furoscix revenue at or below the first-half 2026 total would also break the case.
The risks this note tracks, each with what would confirm it:
- Furoscix growth after ReadyFlow is slower than management's fourth-quarter statement implies. Confirmed by: fourth-quarter 2026 Furoscix revenue at or below the first-half 2026 total.
- Losses and a shrinking cash balance keep pressure on a leveraged balance sheet. Confirmed by: cash and investments below the $96.6 million reported at 30 September 2026 alongside another GAAP net loss.
- Selling-stockholder shares registered on 21 August 2026 add supply after the rally. Confirmed by: filings showing sales of the 12,853,470 registered shares.
- Revenue keeps falling short of analyst estimates, as it did in the third quarter, and the guidance does not offset it. Confirmed by: fourth-quarter 2026 total revenue below consensus estimates at the report.
What it trades with
No current theme cluster carries MannKind. The shares trade on the Furoscix sales trend, on United Therapeutics' Tyvaso DPI sales through the royalty line, and on small-cap biopharma financing conditions given the $319.4 million term loan. One quarter of ReadyFlow-era Furoscix sales is too small a sample to show a trend.
CEO Michael Castagna and CFO Chris Prentiss are scheduled to present in London at a UBS fireside chat on 17 November 2026 and at Jefferies on 18 November 2026, according to MannKind's 10 November 2026 release.
The evidence, claim by claim (8)
- Third-quarter 2026 total revenue was $101.9 million, up 24% from $82.1 million a year earlier; Furoscix net revenue was $22.4 million and Afrezza net sales were $19.3 million, up 5%. MannKind Q3 2026 results, Form 8-K exhibit 99.1 · as of
- Total royalty revenue was $37.5 million, up 12% from $33.3 million, which MannKind attributes to higher United Therapeutics Tyvaso DPI net revenue. MannKind Q3 2026 results, Form 8-K exhibit 99.1 · as of
- GAAP net loss was $23.2 million ($0.07 per share) versus net income of $8.0 million a year earlier; non-GAAP adjusted net loss was $3.6 million ($0.01 per share). MannKind Q3 2026 results, Form 8-K exhibit 99.1 · as of
- Furoscix ReadyFlow shipments began in mid-September and about 75% of Furoscix shipments were ReadyFlow by late October; CEO Michael Castagna said fourth-quarter Furoscix revenue should exceed the first half of 2026. MannKind Q3 2026 results, Form 8-K exhibit 99.1 · as of
- Cash, cash equivalents and investments were $96.6 million and the term loan was $319.4 million; the senior convertible notes were fully repaid. MannKind Q3 2026 results, Form 8-K exhibit 99.1 · as of
- Adjusted earnings per share of $(0.01) beat the $(0.06) estimate, while revenue of $101.87 million missed the $107.75 million estimate. Benzinga earnings summary · as of
- Cantor Fitzgerald maintained Overweight and raised its price target to $10; RBC Capital maintained Sector Perform and raised its target to $5. Benzinga analyst rating actions · as of
- Director Steven Binder sold 39,051 shares at $3.29 on 25 September 2026 under a Rule 10b5-1 plan. SEC Form 4 filed 28 September 2026 · as of
Sources